PDCD1 and cancer: In the cohort for analysis, ICI users (71,183 patients; median age at diagnosis, 61 years; male, 77%) and PD1 inhibitor users (64,429 patients; median age at diagnosis, 61 years; male, 76%) were more likely to have adrenal metastasis, hypertension, diabetes and prior cancer treatment at baseline (Table 1 and Supplementary Table 5), and likewise when measured at the index date (Supplementary Table 6).